Loading...
01/10 23:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with net revenue and EBITDA growth, positive surgical case growth, and solid liquidity. The Q&A section indicates positive sentiment with confidence in cash flow improvement and stable payer mix. Despite high leverage, the management expects improvement. The guidance aligns with strategic goals, and no significant risks were flagged. Considering the company's market cap, a positive stock price movement (2% to 8%) is likely in the next two weeks.
Net Revenue $776,000,000 (up 8% year-over-year) due to strong organic growth and contributions from surgical case growth.
Adjusted EBITDA $103,900,000 (up nearly 7% year-over-year) attributed to operational efficiencies and growth in surgical cases.
Surgical Cases Over 160,000 cases performed (up 4.5% year-over-year), with significant growth in GI and orthopedic procedures.
Same Facility Revenue Growth 5.2% increase year-over-year, consistent with growth algorithm target of 4% to 6%.
Cash Flow from Operations $6,000,000 reported, impacted by timing of working capital activities and higher distributions to physician partners.
Distributions to Physician Partners $62,000,000 (higher than prior year) due to timing of distributions and stronger results in the previous quarter.
Total Liquidity Over $615,000,000, combining cash and revolver capacity, indicating strong financial position.
Corporate Debt $2,200,000,000 with no maturity until 2030, effective interest rate fixed at approximately 6%.
Net Debt to EBITDA Ratio 4.1 times, consistent with expectations due to recent acquisitions.
Leverage Ratio 4.8 times calculated using consolidated debt, expected to decrease with continued earnings growth.
Acquisition Spending $55,000,000 deployed for five surgical facilities at an effective multiple under eight times adjusted EBITDA.
Maintenance Capital Expenditures $6,000,000 incurred in the first quarter.
Surgical Robots Investment: Invested in 68 surgical robots to enable physicians to perform more complex and higher acuity procedures.
De Novo Facilities: Opened 8 de novo facilities in 2024, with 20 total since 2022 and 10 currently under construction.
Same Facility Revenue Growth: Same facility revenue growth expected to be at or above 6% for 2025, with a balanced growth between volume and rate.
Surgical Case Growth: Surgical case growth of 6.5% in Q1 2025, with a focus on lower acuity specialties.
Operating Efficiency: Continued improvements in cash conversion and operating efficiencies, with days sales outstanding decreasing by 2 days.
Margin Expansion: Slight margin pressure in Q1 due to business mix, but confidence in annual margin expansion remains.
Acquisition Strategy: Deployed $55 million in 2025 for 5 surgical facilities, with a robust pipeline for future acquisitions.
Regulatory Positioning: Minimal exposure to tariff-related price increases and legislative changes, with less than 5% revenue exposure to Medicaid.
Regulatory Environment: Surgery Partners is navigating significant regulatory uncertainty, particularly concerning tariffs and potential legislative changes to Medicaid and exchange-based reimbursement programs. However, the company reports minimal exposure to tariff-related price increases and considers changes to Medicaid as not posing a risk to growth.
Supply Chain Challenges: The company has confidence in its supply chain management, with 70% of purchasing through HealthTrust, which provides transparency and mitigates risks related to tariffs. They do not foresee material supply chain risks in the near to midterm.
Competitive Pressures: Surgery Partners faces competitive pressures in the healthcare market, particularly in pricing and payer negotiations. However, they maintain strong relationships with payers and believe they are well-positioned as a low-cost alternative.
Economic Factors: The company anticipates headwinds from increased interest expenses due to the expiration of an interest rate swap, which may impact cash flows in the latter part of the year.
Acquisition and Integration Costs: The level of M&A activity has led to higher than typical transaction and integration costs, which are expected to normalize in the second half of 2025.
Labor Dynamics: There are ongoing pressures related to labor costs, particularly in specialty areas like anesthesia, but the company does not see this as a major headwind for 2025.
Net Revenue Q1 2025: Surgery Partners reported first quarter net revenue of $776 million, reflecting an 8% increase compared to the prior year.
Adjusted EBITDA Q1 2025: Adjusted EBITDA for the first quarter was $103.9 million, a nearly 7% increase year-over-year.
Same Facility Revenue Growth: The company expects full year 2025 same facility growth to be at or above 6%, with a balanced growth between volume and rate.
Surgical Cases: Over 60,000 surgical cases were performed in Q1 2025, with a 6.5% growth in surgical cases.
De Novo Facilities: Surgery Partners opened 8 de novo facilities in 2024 and currently has 10 under construction, with a robust pipeline for future development.
Physician Recruitment: In Q1 2025, nearly 50 new physicians were added, with a focus on orthopedic specialties.
Acquisitions: In 2025, $55 million was deployed for five surgical facility acquisitions at an effective multiple under 8 times adjusted EBITDA.
2025 Revenue Guidance: Full year 2025 revenue guidance is reaffirmed to be in the range of $3.3 billion to $3.45 billion.
2025 Adjusted EBITDA Guidance: Adjusted EBITDA guidance for 2025 is reaffirmed to be in the range of $555 million to $565 million.
Margin Expansion: The company expects continued margin expansion in line with its long-term growth algorithm.
Cash Flow: Surgery Partners anticipates improved cash flow generation as the year progresses, despite some headwinds from interest costs.
Acquisitions in 2025: Surgery Partners deployed $55,000,000 to acquire five surgical facilities at an effective multiple under eight times adjusted EBITDA.
Liquidity: The company ended the quarter with $229,000,000 in cash and over $615,000,000 in total liquidity, sufficient to fund growth without tapping capital markets.
M&A Strategy: The company targets around $200,000,000 of M&A annually, assuming stable pricing and historical earnings multiples.
Debt and Leverage: The company has $2,200,000,000 in corporate debt with a target leverage ratio of sub 3 times, currently at 4.1 times.
Distribution to Partners: Surgery Partners distributed $62,000,000 to physician partners in Q1 2025, higher than the prior year due to timing.
The earnings call presents mixed signals. Strong growth in orthopedic procedures and revenue guidance reaffirmation are positive. However, weaker-than-expected demand, a reduction in acquisition spending, and a $20 million EBITDA guidance cut are concerning. Management's uncertainty about macroeconomic factors and payer mix changes adds to the ambiguity. The market cap suggests moderate sensitivity, leading to a neutral prediction.
The earnings call highlights strong financial performance, with revenue and EBITDA growth, strategic expansion in ASC, and positive outlooks on partnerships and market trends. The Q&A reveals stable payer behavior, promising robotics investments, and a large TAM. Despite some management vagueness and lower EBITDA guidance, the overall sentiment is positive, supported by growth initiatives and reaffirmed guidance. Given the market cap, a 2%-8% stock price increase is expected.
The earnings call summary shows strong financial performance with 7% EBITDA growth, 5.2% same-facility revenue growth, and stable debt metrics. The Q&A section confirms constructive payer negotiations and consistent payer mix, with positive outlooks for cash flow and M&A activities. Despite some unclear responses, the overall sentiment is positive, supported by improved liquidity and strategic growth plans. Given the company's market cap, the stock is likely to experience a moderate positive reaction, estimated between 2% to 8%.
The earnings call highlights strong financial performance with net revenue and EBITDA growth, positive surgical case growth, and solid liquidity. The Q&A section indicates positive sentiment with confidence in cash flow improvement and stable payer mix. Despite high leverage, the management expects improvement. The guidance aligns with strategic goals, and no significant risks were flagged. Considering the company's market cap, a positive stock price movement (2% to 8%) is likely in the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
